XELOX plus bevacizumab vs. FOLFIRI plus bevacizumab treatment for first-line chemotherapy in metastatic colon cancer: a retrospective study of the Anatolian Society of Medical Oncology

dc.contributor.authors	Duran AO, Karaca H, Besiroglu M, Bayoglu IV, Menekse S, Yapici HS, Yazilitas D, Bahceci A, Uysal M, Sevinc A, Hacibekiroglu I, Aksoy A, Tanriverdi O, Arpaci E, Inanc M, Dane F, Ozkan M
dc.date.accessioned	2020-02-27T08:41:24Z
dc.date.available	2020-02-27T08:41:24Z
dc.date.issued	2014
dc.identifier.citation	Duran AO, Karaca H, Besiroglu M, Bayoglu IV, Menekse S, Yapici HS, Yazilitas D, Bahceci A, Uysal M, Sevinc A, Hacibekiroglu I, Aksoy A, Tanriverdi O, Arpaci E, Inanc M, Dane F, Ozkan M (2014). XELOX plus bevacizumab vs. FOLFIRI plus bevacizumab treatment for first-line chemotherapy in metastatic colon cancer: a retrospective study of the Anatolian Society of Medical Oncology. Asian Pac J Cancer Prev, 15(23), 9-10375
dc.identifier.uri	https://hdl.handle.net/20.500.12619/66724
dc.title	XELOX plus bevacizumab vs. FOLFIRI plus bevacizumab treatment for first-line chemotherapy in metastatic colon cancer: a retrospective study of the Anatolian Society of Medical Oncology
dc.identifier.volume	15(23)
dc.identifier.startpage	10375
dc.identifier.endpage	9
dc.contributor.department	Sakarya Üniversitesi/Tıp Fakültesi/Dahili Tıp Bilimleri Bölümü
dc.contributor.saüauthor	Bayoğlu, İbrahim Vedat
dc.relation.journal	Asian Pac J Cancer Prev
dc.contributor.author	Bayoğlu, İbrahim Vedat